Molecular profiling of tumors
Inventors
Von Hoff, Daniel D. • Loesch, David M. • Alarcon, Arlet • Penny, Robert J. • Wright, Alan • McGinniss, Matthew J. • Bender, Ryan P. • Pawlowski, Traci
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9064045-B2
Publication Date
2015-06-23
Expiration Date
Abstract
Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.
Core Innovation
The invention provides a system for generating a report identifying a therapeutic agent for an individual with mesothelioma. The system includes at least one nucleic acid sequencing device configured to assay a plurality of molecular targets in a biological sample from the individual to determine molecular profile test values for the plurality of molecular targets, including BRAF, EGFR, PDGFRA, and PI3K.
The system further includes at least one computer database comprising, for each of the plurality of molecular targets, a reference value and a listing of available therapeutic agents. Computer-readable program code inputs the molecular profile test values and compares each molecular profile test value with the corresponding reference value from the computer database, and the comparison is used to access the database and identify at least one therapeutic agent when the comparison indicates a likely benefit.
The system generates a report that comprises a listing of all the molecular targets for which the comparison to the reference value indicates a likely benefit of the at least one therapeutic agent, together with the at least one therapeutic agent identified. The described approach is applied in a context that includes mesothelioma and emphasizes molecular profiling to select candidate therapies.
Claims Coverage
The independent claim covers a report-generating system for an individual with mesothelioma based on nucleic-acid sequencing-derived molecular profile test values for multiple molecular targets. The independent claim includes four inventive features that together support database-based comparison, therapeutic agent identification, and report generation.
Mesothelioma therapeutic agent report based on multi-target molecular profile sequencing
A system for generating a report identifying a therapeutic agent for an individual with mesothelioma, including at least one nucleic acid sequencing device configured to assay a plurality of molecular targets in a biological sample from the individual to determine molecular profile test values for the plurality of molecular targets comprising BRAF, EGFR, PDGFRA, and PI3K.
Database references and therapeutic agent listings per molecular target
At least one computer database comprising a reference value for each of the plurality of molecular targets and a listing of available therapeutic agents for each of the plurality of molecular targets.
Comparison of molecular profile test values to reference values and likely benefit indication
Computer-readable program code instructing the system to input the molecular profile test values and compare each molecular profile test value with a corresponding reference value from the at least one computer database, wherein the comparison indicates a likely benefit of the at least one therapeutic agent.
Report generation listing molecular targets and identified therapeutic agents
Computer-readable program code instructing the system to generate a report that comprises a listing of all the molecular targets for which the comparison to the reference value indicated a likely benefit of the at least one therapeutic agent and the at least one therapeutic agent identified.
Overall claim coverage is directed to a sequencing-to-database comparison workflow that identifies therapeutic agents with likely benefit for a mesothelioma individual and generates a report listing the molecular targets and associated therapeutic agents.
Stated Advantages
Provides a report identifying at least one therapeutic agent for an individual with mesothelioma based on molecular profile test values compared to reference values.
Generates a listing of molecular targets and therapeutic agents associated with likely benefit as indicated by the comparison to reference values.
The comparison indicates a likely benefit of a therapeutic agent.
The approach emphasizes molecular profiling to select candidate therapies.
Documented Applications
Therapeutic agent selection for an individual with mesothelioma using molecular profiling and report generation based on likely benefit from database comparisons.
An individual with mesothelioma.
Personalized oncology.
Interested in licensing this patent?